A dose‐adjusted, open‐label, pilot study of the safety, tolerability, and pharmacokinetics of STC3141 in critically ill patients with sepsis

• Main Authors: Rinaldo Bellomo (Author), John Patava (Author), Ruth Van Lancker (Author), Nathalie Layios (Author), Marijke Peetermans (Author), Mark Plummer (Author), Rachid Attou (Author), Robert McNamara (Author), Andrew Udy (Author), Bradley Wibrow (Author), Adam Deane (Author), Edward Litton (Author), Marcel Tanudji (Author), Fuhong Su (Author), Zhang Zhong (Author), Linda Shi (Author), Li Ning (Author)
• Format: Book
• Published: Wiley, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Increased circulating histones correlate with sepsis severity and are a potential therapeutic target. Pre‐clinical studies showed benefit with a histone‐neutralizing polyanion molecule (STC3141). We aimed to investigate the safety, tolerability, and pharmacokinetics of STC3141 in critically...